Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
about
The role of drug transporters in the kidney: lessons from tenofovirInhibitor-Based Therapeutics for Treatment of Viral HepatitisTenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.Hepatitis B virus: new therapeutic perspectives.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Investigational reverse transcriptase inhibitors for the treatment of HIV.Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.Hepatitis B: Working Towards a Cure.Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.Targeting Cancer Cells with a Bisphosphonate Prodrug.A Review of the Efficacy and Safety of Genvoya(®) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Renal effects of novel antiretroviral drugs.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Tenofovir Alafenamide.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP.Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial.Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapyRare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
P2860
Q26866489-9C840E47-BA3A-43ED-AB10-2F7DF7BDE439Q28073697-E44D3F9A-2D18-4450-A510-4F2746E74579Q30843736-123C9845-7CC0-4B4A-AF15-4E8D9F22F2ECQ34507250-4303D7BE-9972-427F-AB1F-02CC2FDCE514Q35567828-16481986-C6C2-4146-A884-5010C21702A5Q35746114-7E13BD90-1B06-4A72-A241-1E4AA270168AQ36075908-63BAB211-83BC-4E32-B35C-572572017BF3Q36306231-A0638359-3066-4792-91E2-61C80311D87CQ36663586-ED80DBB9-3992-468B-9DF2-A1F7EC9CCEDCQ36988748-7E6F7B54-4EC2-4C4E-95F5-99D089E2B5BCQ37242504-F84DE442-F982-4DDB-AC29-186B18246213Q38447283-5917B607-21AC-4B5F-ABFE-ECB1FA591449Q38520954-BDB33AFA-E5C8-434C-B1F2-2FE92966AB25Q38566984-D96F1C20-18BD-4860-993B-77AA0C76D884Q38609568-F95EC766-E887-4370-AD89-33C76E9334E2Q38661064-7CC9A587-733D-4183-8FA0-DFF73183045EQ38736342-F12F2F7C-2744-4BBE-9A81-4B761B362AD5Q38756133-8905E902-6F51-498C-A1F5-460604DB47CCQ38802093-2ED2FDC2-7A2C-4BF6-95CB-A10ED98D192AQ38836878-80D62F20-89AF-44BE-8ACB-FE74524C34DFQ38837077-803C3B3D-ADCC-4309-B875-1FB4404BEF69Q38865511-4E367632-AC08-40F6-844F-7EECAADBFD69Q38910661-35663998-E7D7-4B4C-B592-F7D66388BE6DQ38984695-46E78409-13F3-4A4B-9BD6-C4D4207B0904Q39002230-67037A91-B78C-46F6-88BE-EFEF5F5BF42CQ39275759-FEA36D2E-FBF8-4783-84FF-8733831C2150Q40386326-779CF400-6B21-4016-9ECD-A73E86727A4FQ40433318-47439306-896E-4536-889A-3A67685FF372Q40654775-19893A71-1A38-43F9-A6FA-9AB6344B0BB9Q40675705-46A30ECC-9428-45F4-8EEC-638B108E7614Q40676324-B474DA15-DE1F-4DFC-9120-B23BC91BA22DQ40785692-AF5E6701-8455-4CC4-B905-75B02070B988Q43882622-392A7424-4F49-449B-AB3A-C4094D1D5186Q45326424-8127B84C-3AEF-4FF0-943B-569DB5A42033Q45334368-81777992-4005-4004-BF5D-134705F488F1Q47611417-FCB19FB7-E52C-4A7C-8406-4B1270085DDFQ50059498-D2C8ED50-4983-4577-95E2-4A8C6EC5E3C1
P2860
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@ast
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@en
type
label
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@ast
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@en
prefLabel
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@ast
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@en
P2093
P2860
P356
P1476
Phase I/II study of the pharma ...... fovir, in HIV-infected adults.
@en
P2093
Andrew Zolopa
Brian Kearney
Dion Coakley
Kathleen Squires
Lijie Zhong
Martin Markowitz
Michael D Miller
Michael Wulfsohn
Peter Ruane
William A Lee
P2860
P304
P356
10.1093/JAC/DKT532
P407
P577
2014-02-06T00:00:00Z